AI, Attention and the Future of Healthcare | GaryVee x Bayer

AI, Attention and the Future of Healthcare | ...

Up next

The #1 Business Skill to Develop in 2026

In this episode of The GaryVee Audio Experience, I talk about the biggest opportunity you have right now: the shift in social media algorithms. I encourage you to do your homework on where your specific audience actually lives, whether that is LinkedIn for executives or TikTok fo ...  Show more

How to Use the Algorithm as Your Real-Time Feedback Loop

In this episode, I sit down on the We Might Be Drunk Podcast to discuss the massive shift happening in media and technology. I encourage you to stop fearing the future and start understanding how AI-driven tools like perfect dubbing and digital avatars are going to provide unpara ...  Show more

Recommended Episodes

Become the CEO of Your Health and Longevity
The So What from BCG

What happens when people live decades longer than before—but not necessarily healthier? Iana Kouris, customer experience leader at BCG X, explores how companies can help people live longer healthier. Businesses can jumpstart the longevity economy by leveraging CX, behavioral desi ...  Show more

Billionaire Naveen Jain Reveals How AI Will Change Medicine Forever | EP #121
Moonshots with Peter Diamandis

In this episode, Peter and Naveen discuss the future of healthcare, how AI will revolutionize our health, and how to raise Moonshot kids.    Recorded on July 22nd, 2024 Views are my own thoughts, not Financial, Medical, or Legal Advice. 05:04 | The Cost of Chronic Diseases 38 ...  Show more

Conference Catch-Up: BIO-Europe 2024
Citeline Podcasts

Biopharma is evolving through collaboration, early-phase deal-making and innovation in precision medicine and AI. At BIO-Europe, Norstella's subject matter experts explored key trends shaping the industry, from market access strategies to sustaining growth through partnerships. I ...  Show more

Terence Flynn: AI Opportunities in Healthcare
Thoughts on the Market

Artificial intelligence could help biopharmaceutical companies reduce costs as well as improve their chances of developing successful new drugs.


----- Transcript -----

Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's Head of U.S. Bi ...

  Show more